Siemens Aktiengesellschaft · XETR:SIE

Siemens Aktiengesellschaft — Siemens — Investor Day (September 2009)

26 slides from Siemens Aktiengesellschaft's investor day presentation, Sep 29, 2009

  1. Slide 1: Siemens Healthcare Diagnostics Division

    Siemens Healthcare Diagnostics Division Donal Quinn CEO Diagnostics Division Capital Market Day Siemens Healthcare London, September 29, 2009 © Siemens AG 2009. All rights reserved.

  2. Slide 2: Safe Harbour Statement

    Safe Harbour Statement This document contains forward-looking statements and information – that is, statements related to future, not past, events. These statements may be identified by words such as “expects,” “looks forward to,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,”

  3. Slide 3: Siemens Healthcare Diagnostics Key data FY 2008

    Siemens Healthcare Diagnostics Key data FY 2008: ƒ Revenue: €3.2bn ƒ Underlying margin: 18.6% ƒ Employees: ~ 14,500 ƒ R&D: ~ €300m © Siemens AG 2009. All rights reserved. Page 3 Sept. 29, 2009 Capital Market Day Healthcare Healthcare Diagnostics

  4. Slide 4: In Vitro Diagnostics – a stable and attractive industry

    In Vitro Diagnostics – a stable and attractive industry Stable medium-term market growth of 5-6% ƒ Growing and aging population ƒ New solutions to improve laboratory efficiency and reduce costs ƒ Disease state orientation Near-term market growth of 3-4% ƒ Economic downturn ƒ Delayed instrument purch

  5. Slide 5: Best offerings to serve laboratory customers of all sizes

    Siemens has the best offerings to serve laboratory customers of all sizes Hospital, Reference & Physician Office Laboratories Labs' challenges Siemens solutions ƒ Integrated systems Cost pressures ƒ Automation solutions ƒ Informatics ƒ Internet-based educational Labor shortages tools ƒ Consulting se

  6. Slide 6: #1 or #2 in eight market segments

    #1 or #2 in eight market segments IVD industry1) €24bn % of revenue Market segment Siemens Immunoassay 1 Chemistry 2 Roche 15% Automation 1 Siemens Other Diabetes 1 42% 68% 14% Blood Gas 2 Cardiac 3 10% Urinalysis 1 Abbott 4% 7% 3% Hemostasis 1 Beckman 5% Becton Coulter Dickinson 13% Hematology 4 J&

  7. Slide 7: Achieving a successful integration

    Achieving a successful integration Operational excellence Cost savings Consolidated operations ƒ Manufacturing Bayer €500m 100% Identified ƒ Logistics Diagnostics ƒ Sales offices Re-engineered processes Diagnostic Dade 65% Realized Products Behring ƒ Product development Corporation ƒ Inventory manag

  8. Slide 8: On track to complete integration activities

    On track to complete integration activities Sales / service offices Logistics sites Distributors 163 76 181 9 9 9 119 74 26 Legal entities Manufacturing Siemens Shared Services ƒ Consolidating numerous ƒ Procurement 123 processes ƒ IT ƒ 1 site closure ƒ Real estate 44 ƒ Finance Achieving €500 millio

  9. Slide 9: Delivering solid financial performance

    Delivering solid financial performance Revenue €m +105% +12% (+3%1)) (+2%1)) 3,185 2,354 2,626 1,553 FY 2007 FY 2008 Q3 YTD Q3 YTD FY 2008 FY 2009 Reported profit Underlying profit2) €m €m 593 445 424 248 241 270 198 Under- Margin 95 lying 7.8% 8.4% 9.2% 17.4% 18.6% 18.9% 16.1% margin 6.1% FY 2007 F

  10. Slide 10: Taking Diagnostics integration to the next level

    Taking Diagnostics integration to the next level Integrating three acquired IVD companies into one Diagnostics Division Accelerating & leveraging the integration of Diagnostics into Healthcare Infrastructure ƒ Support functions ƒ Information technology ƒ Real estate Results Customer relationships ƒ

  11. Slide 11: We will accelerate revenue growth

    We will accelerate revenue growth Positioned for above served market growth 1 New system launches Served Market Siemens 2 Leveraging an expanding test 6% menu across a growing installed 5% base of instruments 4% 3 Emerging market growth 3% 2% 4 Selling and consistently delivering 1% the value of dif

  12. Slide 12: Launching new systems

    1 Launching new systems New features will attract new / retain existing customers Customer benefits Integrated systems Immunoassay systems ƒ Higher quality test results ƒ Faster turnaround time – even with growing test volumes ƒ Lower labor requirements ƒ Lower total costs Dimension® Vista 500 IMMUL

  13. Slide 13: Launching new systems: more automation solutions than any other IVD company

    1 Launching new systems We offer more automation solutions than any other IVD company Customer benefits Automation ƒ Higher quality test results ƒ Faster turnaround time IMMULITE® with higher volume ƒ Lower labor ADVIA® ADVIA Hema- requirements tology Centaur® Siemens Automation Automation installed

  14. Slide 14: Growing our installed base of instruments

    2 Growing our installed base of instruments Installed base drives future test and service revenue Revenue 160,000 th 4-6% Grow 10-15% 140,000 Instruments 120,000 100,000 80,000 85-90% Reagents / 60,000 consumables / service 40,000 20,000 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 FY 2006 FY 2007 FY 20

  15. Slide 15: Leveraging our expanding test menu to drive new revenue opportunities

    Leveraging our expanding test menu to drive new 2 revenue opportunities More than 900 tests across multiple disease states Allergy Immunosuppressive & Anemia / iron metabolism therapeutic drug monitoring Revenue Autoimmune / rheumatoid Infectious disease Bone metabolism Inflammation 10-15% Cancer Li

  16. Slide 16: Diagnostics growth outperforming in emerging markets

    3 Diagnostics growth outperforming in emerging markets Also focusing resources on smaller, high-growth1) markets China +17% p.a. FY 2008 FY 2010E Brazil +5% p.a. India +21% p.a. FY 2008 FY 2010E FY 2008 FY 2010E 1) Revenue growth, year-on-year on a comparable basis, i.e. excluding currency translati

  17. Slide 17: Selling and consistently delivering the value of differentiated service and support

    Selling and consistently delivering the value of 4 differentiated service and support Advancing customer loyalty It's more than products . . . Remote Diagnostics 365 day Informatics Technical Unique products and solutions Support Exceptional service that is valued by customers Lab Tech Differentiate

  18. Slide 18: Consulting services to improve efficiency and reduce costs

    Consulting services to improve efficiency and reduce costs for our customers Reducing a lab's operating costs by 25-60% White River Medical Center, Arkansas % of customers choosing Siemens Improvements following consulting engagement Labor savings 36% (42% test volume increase, without additional FT

  19. Slide 19: High service levels in U.S. contribute to buying decisions

    High service levels in U.S. contribute to buying decisions Overall U.S. service satisfaction1) 6 Siemens #1 #2 #2 #1 Industry Average 5 80% of U.S. revenue 4 Chemistry Immunoassay Hemostasis Microbiology Hematology Molecular U.S. customers' acquisition intent2) Received Pinnacle Award from Premier S

  20. Slide 20: Committed to industry-leading profit margin

    Committed to industry-leading profit margin Key drivers Underlying profit margin Target 16.1% 16-19% Higher revenue growth margin Services and value selling Integration synergies Cost management activities Q3 YTD FY FY 2009 2010E © Siemens AG 2009. All rights reserved. Page 20 Sept. 29, 2009 Capital

  21. Slide 21: Accelerating operational and financial performance

    Accelerating operational and financial performance Focused business strategy Improving Highly profit motivated margin Quality in employees everything we do Driving Executing revenue integration growth © Siemens AG 2009. All rights reserved. Page 21 Sept. 29, 2009 Capital Market Day Healthcare Health

  22. Slide 22: Reconciliation and Definitions for Non-GAAP Measures (I)

    Reconciliation and Definitions for Non-GAAP Measures (I) To supplement Siemens’ Consolidated Financial Statements presented in accordance with International Financial Reporting Standards, or IFRS, Siemens presents the following supplemental financial measures: ƒ New orders; ƒ Adjusted or organic gro

  23. Slide 23: Reconciliation and Definitions for Non-GAAP Measures (II)

    Reconciliation and Definitions for Non-GAAP Measures (II) Adjusted or organic growth rates of Revenue and new orders In its financial reports, Siemens presents, on a worldwide basis and for each Sector and Cross-Sector Business, the percentage change from period to period in Revenue and new orders a

  24. Slide 24: Reconciliation and Definitions for Non-GAAP Measures (III)

    Reconciliation and Definitions for Non-GAAP Measures (III) ROCE at the Siemens group level, on a continuing operations basis Siemens also presents group ROCE on a continuing operations basis. For this purpose, the numerator is Income from continuing operations and the denominator is CE, less Assets

  25. Slide 25: Reconciliation and Definitions for Non-GAAP Measures (IV)

    Reconciliation and Definitions for Non-GAAP Measures (IV) Adjusted industrial net debt Siemens defines adjusted industrial net debt as net debt less (1) SFS debt excluding SFS internally purchased receivables; less (2) 50% of the nominal amount of our hybrid bond; plus (3) the funded status of pensi

  26. Slide 26: Siemens investor relations contact data

    Siemens investor relations contact data Mariel von Drathen +49-89-636-33780 Munich Office +49-89-636-32474 US Office +1-408-464-2004 Internet: http://www.siemens.com/investorrelations Email: investorrelations@siemens.com Fax: +49-89-636-32830 © Siemens AG 2009. All rights reserved. Page 26 Sept. 29,

Siemens — Investor Day (September 2009) on 6ix